AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Discover the best timing for robo versus manual investing in 2026. This intro outlines criteria, costs, and expected outcomes to guide your choice.
26,911 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
A single fund's exit from Klaviyo set off a ripple effect that shaved a chunk from the stock after earnings. This art...
Insider moves can reveal more than a single trade. This article breaks down the photonics director sells 1,511, expla...
Mesirow Financial Investment Management revealed a substantial new holding in the Akre Focus ETF. This piece explains...
A big fund move can shift sentiment and pricing. This article breaks down the implications of baillie gifford dumps 2...
Tech-focused investors watched TeraWulf surge after a major AI data-center lease deal, signaling potential recurring ...
Bridgewater Associates tightened its tech exposure in the latest 13F filing, cutting stakes in Microsoft, Meta, and A...
A prominent investor placed a sizable stake in Nektar Therapeutics, sparking questions about the stock's potential. T...
A veteran Jefferies strategist outlines a split AI spend cycle: upfront hardware capex drives early gains, while long...
NVIDIA is expanding beyond its GPU roots to build a broad AI infrastructure platform, funded by a growing investment ...
SpaceX rumors spark a rally in the Procure Space ETF, with the fund tracking the space economy as investors eye a pot...
A dramatic insider move at Apogee comes after a steep stock rise. This article breaks down the possible meanings, ris...